Anika Therapeutics Analyst Price Targets

Anika Therapeutics Inc

ANIKNASDAQ

Trade with Public

$19.98

-0.71-3.43%

最終更新: Oct 16, 4:00 PM

$19.98

-0.71-3.43%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Anika Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Anika Therapeutics (ANIK).

Price Target Range — 11 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$21Upside to Avg. PT+6.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 18, 2026	B. Riley Securities	Madison El-Saadi	Assumes	Buy	$21→$23
Jul 30, 2026	B. Riley Securities	Anderson Schock	PT Raise	Buy	$18→$21
Feb 27, 2026	Barrington Research	Michael Petusky	PT Raise	Outperform	$16→$17
Jan 9, 2026	Barrington Research	Michael Petusky	Maintained	Outperform	$16
Nov 6, 2025	Barrington Research	Michael Petusky	PT Raise	Outperform	$15→$16
Sep 23, 2025	Barrington Research	Michael Petusky	Maintained	Outperform	$15
Jul 31, 2025	Barrington Research	Michael Petusky	PT Cut	Outperform	$19→$15
May 12, 2025	Barrington Research	Michael Petusky	PT Cut	Outperform	$20→$19
Mar 13, 2025	Barrington Research	Michael Petusky	PT Cut	Outperform	$25→$20
Nov 1, 2024	Barrington Research	Michael Petusky	PT Cut	Outperform	$37→$25
Oct 22, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$37
Aug 9, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$37
May 29, 2024	Stephens & Co.	George Sellers	Maintained	Equal-Weight	$24
May 9, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$37
Mar 14, 2024	Stephens & Co.	George Sellers	Maintained	Equal-Weight	$22
Mar 14, 2024	Barrington Research	Michael Petusky	PT Raise	Outperform	$29→$37
Jan 3, 2024	Barrington Research	Michael Petusky	PT Raise	Outperform	$28→$29
Nov 3, 2023	Barrington Research	Michael Petusky	PT Raise	Outperform	$24→$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

B. Riley Securities analyst Anderson Schock maintains Anika Therapeutics (NASDAQ:ANIK) with a Buy and raises the price target from $18 to $21.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $16 price target.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the price target from $15 to $16.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $15 price target.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the price target from $19 to $15.

Benzinga Newsdesk

Anika Therapeutics Inc

Anika Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

ニュース

パートナーシップ

ベンジンガ・グローバル

Anika Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

Anika Therapeutics Inc

Anika Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PROB. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

ニュース

パートナーシップ

ベンジンガ・グローバル

Anika Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PROB. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15